Skip to content

Pacira BioSciences

US · PCRX #3244 by market cap
36.48 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-19 19:54

Valuation each multiple against its own 5-year range

P/B ratio 2.05 In line with history 62nd percentile
5-year average 2.05 · #42 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 39.20 In line with history 44th percentile
5-year average 29.09 · forward 33.78 · #17 of 26 in Drug Manufacturers - Specialty & Generic
P/S ratio 1.97 In line with history 52nd percentile
5-year average 2.44 · forward 1.91 · #36 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Pacira BioSciences (PCRX) 1.46B 39.23 2.05 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value42.49 Economic moatNone UncertaintyLow

Trading 16.5% below Morningstar's fair value estimate.

Fair value

Pacira BioSciences Inc earns a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 14% discount to our quantitative fair value estimate of $42.49 per share, which is reinforced by this estimate's low uncertainty rating.

The firm's profitability strengthens our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 5.2%, which ranks in the top 45% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 4.9, for example, sits in the bottom 45% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. This characteristic further promotes our favorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-19 19:54:59 · For reference only, not investment advice and not tailored to your situation.

Pacira BioSciences discussion 0 comments

Add a comment